Related Experiment Video
Updated: May 3, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma
Diona L Damian1, Robyn P M Saw, John F Thompson
1Department of Dermatology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; The University of Sydney at Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Melanoma Institute Australia, North Sydney, New South Wales, Australia.
Abstract:
Topical diphencyprone (DPCP) can be used to treat in transit and cutaneously metastastatic melanoma. To date, 50 patients have received DPCP therapy for at least 1 month at our institution, with complete clearance of cutaneous disease in 46% and partial response in a further 38% of patients. Topical immunotherapy with DPCP is inexpensive and well-tolerated and should be considered in patients with skin metastases unsuitable for or refractory to other forms of therapy.

